Immunomodulatory derivatives of thalidomide (IMiD compounds) like lenalidomide (LEN) have impressive clinical activity in patients with both relapsed or refractory and newly diagnosed multiple myeloma. 1 Hematopoietic stem cell (HSC) transplantation is still the 'backbone' in the treatment of newly diagnosed multiple myeloma patients and very often combined with LEN in order to achieve high response rates. 2 Unfortunately, clinical data have shown that in up to 43% of patients, standard mobilization with granulocyte colony-stimulating factor (G-CSF) alone failed to mobilize hematopoietic progenitors, raising concerns about potential stem cell toxicity of LEN. 3, 4 We have shown that neither LEN nor pomalidomide (POM) are toxic to HSC, 5, 6 and it is known that mobilization of CD34 þ cells with Plerixafor (AMD3100) overcomes mobilization failures after LEN treatment. 7 The fact that AMD3100 antagonizes the binding of the chemokine stromal-cell-derived factor-1a (SDF-1a) to its receptor CXC chemokine receptor 4 (CXCR4) suggests a potential role of the CXCR4/SDF-1a axis in mediating mobilization failure after LEN treatment. To further analyze why blocking CXCR4 by AMD3100 overcomes mobilization failure to G-CSF in LEN-treated patients, we analyzed the effects of LEN on CXCR4 expression and function in CD34 þ cells. We first analyzed CXCR4 expression in CD34 þ cells treated with LEN and POM. Flow cytometry analysis indicated that the CD34 þ cells were treated with indicated concentrations of LEN 10 mm, POM 10 mm or DMSO 0.01% as control for 24 h, followed by mRNA extraction and reverse transcription. Complementary DNA was subjected to real-time PCR. (c) CD34
þ cells were treated with LEN for indicated time, and total protein was extracted followed by western blot. (d) CD34
þ cells were treated with LEN 10 mm or DMSO 0.01% as control for 48 h, and membrane and cytosol fractions were extracted separately. CXCR4 protein levels were compared by western blot, and ATPase and b-actin were used as loading control for the two fractions. (e) CD34 þ cells were treated with LEN 10 mm or DMSO 0.01% as control for 48 h, and then cells were fixed and stained for membrane CXCR4 (green color). The cells were also counterstained with DRAQ5 for nuclear staining (blue color). The localization of CXCR4 was observed under Leica TCSSL confocal microscope (Leica Microsystems Inc., Buffalo Grove, IL, USA). (f ) CD34 þ cells were treated with indicated dosage of LEN, POM or DMSO 0.01% as control for 24 h, followed by mRNA extraction and reverse transcription. SDF-1a mRNA levels were compared by real-time PCR. (g) Bone marrow stromal cells were treated with indicated dosage of LEN, POM or DMSO 0.01% for 48 h, and then subjected to enzyme-linked immunosorbent assay analysis to detect SDF-1a secretion. cells surface after 3 or 6 days of treatment (Supplementary Figure 1) . This is in accordance with a study by Ximeri et al. 8 They reported that CXCR4 expression significantly increased in CD34 þ cells following LEN treatment compared with baseline in low-risk MDS patients with del(5q). They concluded that LEN improves the adhesion of HSC to the bone marrow niche by inducing the CXCR4/SDF-1a interactions between the HSC and stromal cells. 8 However, the mechanisms underlying the effects of LEN on CXCR4/SDF-1a interactions are poorly understood.
It is known that the cell surface expression of CXCR4 can be low, whereas a large part of CXCR4 protein is sequestered intracellularly in CD34 þ cells. 9 To investigate whether the increased CXCR4 surface expression after LEN exposure was due to an increase of total CXCR4 expression or CXCR4 translocation from the cytoplasm þ cells were treated with dimethyl sulfoxide (DMSO) 0.01%, LEN 10 mm or POM 10 mm, and total protein was extracted and treated with or without PNGase F for deglycosylation. The CXCR4 levels were detected by western blot, and b-Actin was used as loading control. Band intensities were normalized to actin and compared with control (e) CD34 þ cells were pretreated with LEN, POM or DMSO as control as indicated. After 48 h, cells were seeded in the upper chamber with or without AMD3100 (0.5 mg/ml). SDF-1a 100 ng/ml was added to the media into the lower chamber. After 12 h, migrated cells in the lower chamber were collected and counted by flow cytometry. The percentage of migrated cells relative to the wholecell number is shown. All experiments were performed in triplicates. Asterisks indicate significant difference with Po0.05 in comparison with control.
to the cell membrane, we performed real-time PCR and western blot assays to determine the total CXCR4 mRNA and protein level. We found that neither LEN nor POM increased the total CXCR4 mRNA or CXCR4 protein level (Figures 1b and c) . But separate analysis of the hydrophobic (membrane) and the hydrophilic (cytosol) cell fraction by western blot revealed that the CXCR4 protein significantly increased in the membrane portion after LEN treatment, suggesting the translocation of CXCR4 to the CD34 þ cell surface (Figure 1d ). The translocation of CXCR4 to the cell membrane induced by LEN was further confirmed by immunofluorescence microscopy. In CD34 þ cells without treatment, CXCR4 showed an even localization in the whole cell. In contrast, LEN treatment induced the cell surface accumulation of CXCR4 in CD34 þ cells as seen in Figure 1e . To exclude that the decreased mobilization of CD34 þ cells after LEN treatment is due to induction of SDF-1a in the bone marrow niche, we analyzed the expression of SDF-1a in CD34 þ cells and human bone marrow stromal cells treated with LEN. In CD34 þ cells treated with LEN or POM, we did not observe increased SDF1a mRNA levels (Figure 1f ) and SDF-1a was not measurable in the supernatants of LEN-treated CD34 þ cells (data not shown). Secretion of SDF-1a by bone marrow stromal cell was unaffected after treatment with LEN or POM (Figure 1g ). These results further suggest that the upregulation of cell surface expression of CXCR4 is due to membrane translocation induced by LEN and POM.
It is very well known that SDF-1a induces internalization of CXCR4. 10 For this reason, we investigated the effect of LEN on SDF1a-induced CXCR4 internalization. By flow cytometry we observed that treatment of CD34 þ cells with SDF-1a induced internalization of CXCR4 in 60±3% of the cells, whereas concomitant treatment with LEN and POM significantly inhibited the SDF-1a-induced internalization of CXCR4 to 36% ± 3% (LEN) and 15% ± 8% (POM) of the cells, respectively (Figure 2a) . Those findings were confirmed by immunofluorescence assays. As expected treatment of CD34 þ cells with SDF-1a-mediated CXCR4 internalization (Figure 2bi vs 2bii) , whereas pretreatment of CD34 þ cells with LEN decreased SDF-1a-induced internalization (Figure 2biii vs  2biv) . To better visualize the dynamic translocation of CXCR4 in response to LEN and SDF-1a, we generated a stable green fluorescent protein (GFP)-CXCR4-expressing Hela cell line. This provided an ideal tool to examine the localization of CXCR4 in live cells under a fluorescence microscope. GFP-tagged CXCR4 localized evenly to the cell membrane of control-treated cells (Figure 2ci ). After SDF-1a treatment, CXCR4 internalized into the endosome and was visible as unevenly distributed dots in the cell cytoplasm (Figure 2cii ). Without SDF-1a, treatment with LEN had no significant effects on the CXCR4 distribution pattern (Figure 2c iii), whereas in the presence of SDF-1a, LEN decreased the internalization of CXCR4 (Figure 2c iv) .
CXCR4 is a 45 kDa seven-transmembrane domain receptor and post-translational modifications such as N-glycosylation induce structural changes of CXCR4 impacting the response to SDF-1a. 11 Therefore, we investigated the effect of LEN on the glycolysation of CXCR4 as potential mechanism how LEN regulates localization of CXCR4. Western blot carried out under conditions to detect glycolysation visualized an additional 66-KDa band of CXCR4 reflecting the N-glycosylated CXCR4 according to the reported molecular weight. 12 As expected in the presence of PNGase F an N-glycosidase, no glycosylated band was detectable in the control CD34 þ cells or after treatment with LEN or POM. The baseline 45-KDa band reflecting unglycosylated CXCR4 was unchanged. In the absence of PNGase F treatment, LEN and POM-induced N-glycosylation reflected by an increased 66-KDa band in comparison with control, with concomitant decrease of the unglycosylated CXCR4 (Figure 2d ). It is known that receptor glycosylation regulates internalization of surface receptors. 13 Further, N-glycosylation is not necessary for high-affinity agonist binding, but has a strong effect on the availability of receptor molecules on the plasma membrane with decreased internalization.
14 These findings suggest that LEN-induced N-glycosylation of CXCR4 contributes to the increased CXCR4 surface expression by inhibiting internalization. In accordance with the increased CXCR4 surface expression, transwell migration assays revealed that in comparison with controls, LEN or POM treatment significantly promoted the SDF-1a-induced migration of CD34 þ cells (Po0.05) by 52% and 72%, respectively. Treatment with AMD3100 completely inhibited migration due to the blockage of response to SDF-1a (Figure 2e ). Previous studies reported that G-CSF decreases SDF-1a expression resulting in increased mobilization of CD34 þ cells. 10 Blockage of internalization of CXCR4 by LEN might increase the binding of CD34 þ to stromal-derived SDF-1a and thereby to the bone marrow niche and subsequently anatagonize the effects of G-CSF. Accordingly, we postulate that AMD3100 overcomes the LENdependent retention of CD34 progenitor cells in marrow following mobilization with G-CSF by blocking the interaction between the LEN-unregulated CXCR4 expression and its ligand SDF-1a.
The current study provides novel insights into a potential mechanism of LEN-induced failure of mobilization of HSC with G-CSF alone. Here, we show that LEN induces localization of CXCR4 to the cell surface and blockage of receptor internalization increases migration to SDF-1a. Increased binding of CXCR4 to SDF1a secreted by the bone marrow niche might subsequently block the mobilization of CD34 þ cells. Blocking the CXCR4 receptor by AMD3100 disrupts this circle and finally permits the mobilization of hematopoietic cells from the bone marrow niche into peripheral blood.
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